1. Home
  2. EVGN vs NEUP Comparison

EVGN vs NEUP Comparison

Compare EVGN & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evogene Ltd

EVGN

Evogene Ltd

HOLD

Current Price

$1.07

Market Cap

10.9M

Sector

Industrials

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$3.97

Market Cap

10.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVGN
NEUP
Founded
1999
1996
Country
Israel
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
10.9M
10.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EVGN
NEUP
Price
$1.07
$3.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$3.50
$21.00
AVG Volume (30 Days)
47.7K
103.5K
Earning Date
11-20-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,016,000.00
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
$12.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.19
N/A
52 Week Low
$0.95
$2.90
52 Week High
$2.42
$21.40

Technical Indicators

Market Signals
Indicator
EVGN
NEUP
Relative Strength Index (RSI) 39.20 35.97
Support Level $1.07 $4.10
Resistance Level $1.12 $4.65
Average True Range (ATR) 0.05 0.25
MACD 0.00 0.15
Stochastic Oscillator 21.05 4.02

Price Performance

Historical Comparison
EVGN
NEUP

About EVGN Evogene Ltd

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: